Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Commercial Development: In August 2025, Jocasta Neuroscience raised $35 million in Series A funding to advance JN-0413, a proprietary -klotho formulation, through Phase 1 trials with IND submission planned for Q4 2026
Because Wegovy significantly suppresses appetite, many patients eat considerably less raising the risk of inadequate protein intake, which can lead to muscle loss alongside fat loss
Advanced Nutrition and Human Metabolism
[16] Refer to the current BNF monograph and NICE guidance for full prescribing criteria
The expected launch of Mazdutide will be the first domestic GLP-1 medicine with indications for both obesity and diabetes
US$ 21.21
US$ 21.88
US$ 28.13
